AstraZeneca

1Q Revenues: $7 billion (+13%)

1Q Earnings: $1.6 billion (+10%)

Comments: Growth in the quarter was driven by combined sales of five key products: Nexium, Seroquel, Crestor, Arimidex and Symbicort, up 17% to $3.6 billion. R&D expenses were $1.2 billion in the quarter, up 36%. In the quarter, the company decided to terminate its licensing and collaboration agreement with AtheroGenics Inc., resulting in charges totaling $83 million.

News from our sister sites